Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMArT-HS: Nicorandil for Hippocampal Sclerosis of Aging
NCT04120766Phase 2Active, not recruiting
- Start
- Dec 2021
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nicorandil in hippocampal sclerosis (MTS) (2 arms). Primary endpoint: Frequency of treatment-related adverse events at 96 weeks. Started Dec 2021; status: active, not recruiting.
02
Drugs
nicorandil
03
Conditions
hippocampal sclerosis (MTS)
Beyond the preview
Go deeper on NCT04120766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120766.